Daily monitoring of glucose levels is an essential part of managing diabetes. However, blood glucose testing usually involves finger pricks, an invasive procedure that is troublesome to some patients. Therefore, increasing efforts have been made to develop a non-invasive method by self-testing salivary glucose levels, which are two orders of magnitude lower than those in blood.
Metabolomics reveals biological insights otherwise unseen. For a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest are needed to uncover actionable insights that propel new therapeutic developments. A specific combination of liquid chromatography-mass spectrometry (LC-MS) technology and biochemical expertise is required to identify this biomarker of interest and develop an assay that is sensitive enough to explore it fully.
At Metabolon, we understand the crucial role glucose plays in diabetes, and we’ve established best-in-class expertise. This glucose assay can be used to track salivary levels and enhance biological understanding in clinical research.
(Scroll left/right to see full table)
| LLOQa |
|---|
| Saliva |
| 125 ng/mL |
aLower Limit of Quantitation (LLOQ) varies for each sample type.
LC-MS/MS: LC-MS/MS (Agilent 1290 UHPLC/Sciex QTrap 5500)
(Scroll left/right to see full table)
| Sample Type | Sample Requirements |
|---|---|
| Saliva | ≥ 300 µL |
Others on request
Disclaimer: This panel is for Research Use Only and is not to be used for diagnostic purposes.
Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover more than 1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.
Heart disease is a leading cause of death worldwide, and there are numerous factors that lead to this and other cardiovascular diseases (CVD). Metabolomics can illuminate cardiovascular disease at multiple levels. In preclinical studies, such as with cardiomyocytes or heart tissue from model organisms, understanding mitochondrial function, energetics, and redox status can drive critical insights into disease mechanisms. In human studies, metabolomics offers the opportunity to account for well-established CVD risk factors such as cholesterol and complex lipids, while simultaneously profiling thousands of other biochemicals in an unbiased fashion to enable the discovery of novel disease mechanisms and biomarkers.
Diabetes is a serious metabolic condition affecting more than 37 million Americans and 460 million people worldwide according to the most recent report from the Centers for Disease Control. Despite being a worldwide epidemic, much remains unknown about individual risk factors for diabetes development, and research is currently being done to identify new and effective treatment for diabetes at all stages. By facilitating assessment of specific metabolic pathways impacted by diabetes, targeted metabolomics can be a critical tool used to identify biomarkers of disease development for early intervention and novel targets to control disease progression, as well for the development of new pharmaceuticals with specific mechanisms of action.
It is well-established that a low-carbohydrate, high-fat ketogenic diet (KD) can help treat refractory epilepsy, which affects more than a third of epileptic patients who don’t respond to existing anticonvulsive drugs. What scientists haven’t understood until recently is how this kind of diet translates to brain activity. The answer for this aspect of epilepsy lies in the gut microbiome. There are many other neurological disorders like Alzheimer’s disease, ALS, Parkinson’s disease, and more. While so much remains to be understood about brain science, we do know that metabolomics is uniquely poised to understand the brain because of the ability of metabolites, small molecules, to cross the blood-brain barrier providing unique insights.
Recognized for our cutting-edge approach to metabolomics, Metabolon has been a valued resource for COVID-19 researchers worldwide. Our actionable metabolomic insights have fueled pivotal and high-profile studies like the National Institute of Allergy and Infectious Diseases (NIAID) IMPACC study research to improve understanding of high-risk patients and the Institute for Systems Biology research to improve understanding of high-risk patients. These and other metabolomics projects with actionable insights at Metabolon are helping get closer to the phenotype and pressing forward on COVID-19 answers.
The liver is the single most important regulator of metabolic homeostasis at the organismal level. That makes metabolomics an indispensable tool for capturing an integrative profile of an individual’s liver function. As the incidence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) continues to rise, researchers and health-care providers can look to Metabolon to provide much-needed non-invasive diagnostic and prognostic indicators as well as a fundamental understanding of pathological processes. The metabolome integrates an individual’s genetic makeup and gene expression profile with nongenetic factors such as diet, environmental exposures, and the microbiome. Therefore layering metabolomic analysis onto genomic and transcriptomic data provides the best opportunity to understand disease.
Once you see the full value of metabolomics, the only remaining question is: who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare.
Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.
Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.
Coverage
Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities
Comparability
Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time
Competency
Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations
Capacity
Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address
P.O. Box 110407
Research Triangle Park, NC 27709
Phone
+1 (919) 572-1711
Fax
+1 (919) 572-1721
International Headquarters
Metabolon GmbH
Zeppelinstraße 3
85399 Hallbergmoos
Germany
